Marshall Wace
IMMX icon

Marshall Wace’s Immix Biopharma IMMX Stock Holding History

Marshall Wace’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.5M Buy
1,794,908
+153,356
+9% +$1.42M 0.01% 761
2026
Q1 		$15M Sell
1,641,552
-337,191
-17% -$2.48M 0.01% 806
2025
Q4 		$10.3M Buy
1,978,743
+1,923,708
+3,495% +$7.92M 0.01% 860
2025
Q3 		$115K Buy
+55,035
New +$132K ﹤0.01% 2640

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Marshall Wace's IMMX Position: Q2 2026 in Review

Marshall Wace increased its Immix Biopharma (IMMX) stake by 9.3% in Q2 2026, buying an estimated $1.42M and bringing the position to 1,794,908 shares worth $18.5M. The position accounts for 0.01% of the portfolio, ranked #761.

Marshall Wace first reported a position in IMMX in Q3 2025 and has held it in 4 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Marshall Wace held 1,794,908 shares of Immix Biopharma worth $18.5M as of Q2 2026.
  • Marshall Wace bought 153,356 Immix Biopharma shares in Q2 2026, an estimated $1.42M.
  • Immix Biopharma made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #761 holding.
  • Marshall Wace first reported a position in Immix Biopharma in Q3 2025 and has held it in 4 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.